HR Positive/ HER2 Negative Breast Cancer Pipeline Outlook Report 2024 (Updated)

DelveInsight's, "HR Positive/ HER2 Negative Breast Cancer-Pipeline Insight, 2024," report provides comprehensive insights about 50+ companies and 53+ pipeline drugs in HR Positive/ HER2 Negative Breast Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the HR Positive/ HER2 Negative Breast Cancer Pipeline Report
• Over 50+ HR Positive/ HER2 Negative Breast Cancer companies are evaluating 53+ HR Positive/ HER2 Negative Breast Cancer pipeline therapies in various stages of development, and their anticipated acceptance in the HR Positive/ HER2 Negative Breast Cancer market would significantly increase market revenue.
• The leading HR Positive/ HER2 Negative Breast Cancer Companies working in the market include Regor Therapeuics, Seagen Inc., CytomX Therapeutics, Taizhou EOC Pharma, Chia Tai Tianqing Pharmaceutical Group, AstraZeneca, Daiichi Sankyo Inc., Tyme, Inc., Seagen Inc., Context Therapeutics, Eisai Inc., Shanghai Hengrui Pharmaceutical Co. Ltd., Jiangsu Simcere Pharmaceutical Co., Kind Pharmaceuticals, Merus N.V., Atossa Therapeutics, Roche, and others.
• Promising HR Positive/ HER2 Negative Breast Cancer Pipeline Therapies in the various stages of development include CX-2009, CX-072, Dato-DXd, Capecitabine, Gemcitabine, OP-1250, Ribociclib, Alpelisib, Palbociclib 125mg, Cyclophosphamide, Doxorubicin, and others.
• April 2024: Yongsheng Wang announced a study of Phase 4 clinical trials for Letrozole. Select the Appropriate Population for Adding CDK4/6i to Neoadjuvant Endocrine Therapy in High Risk Early HR+/HER2-breast Cancer Based on Molecular Marker.
• April 2024: Pfizer announced a study of Phase 3 clinical trials for Exemestane, Everolimus, Fulvestrant, and PF-07220060. This study will compare the experiences of participants receiving the study medicine plus fulvestrant to those who are receiving the study doctor's choice of treatment. This will help decide if the study medicine is safe and effective.

Request a sample and discover the recent advances in HR Positive/ HER2 Negative Breast Cancer Treatment Drugs @ HR Positive/ HER2 Negative Breast Cancer Pipeline Outlook Report- https://www.delveinsight.com/sample-request/hr-positive-her2-negative-breast-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

In the HR Positive/ HER2 Negative Breast Cancer pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, HR Positive/ HER2 Negative Breast Cancer NDA approvals (if any), and product development activities comprising the technology, HR Positive/ HER2 Negative Breast Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

HR Positive/ HER2 Negative Breast Cancer Overview
A breast cancer is classified as HR-positive if its cells have receptors for the hormones estrogen and progesterone, which suggests the cancer cells receive signals from these hormones that promote their growth. Cancer tissue is also tested for HER-2 proteins, or receptors, that help control the growth and repair of breast cells in which HER-2-negative breast cancers, have cells that contain little to no HER-2 protein, so they tend to grow more slowly and have a better outlook than HER-2-positive cancers The breast cancer subtype HR+/HER2- is the most common subtype with an age-adjusted rate of 87.4 new cases per 100,000 women, based on 2015-2019 cases.

Find out more about HR Positive/ HER2 Negative Breast Cancer Therapeutics Assessment @ HR Positive/ HER2 Negative Breast Cancer Preclinical and Discovery Stage Products- https://www.delveinsight.com/sample-request/hr-positive-her2-negative-breast-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

HR Positive/ HER2 Negative Breast Cancer Emerging Drugs Profile
Camizestrant: AstraZeneca
Camizestrant is a potent, next-generation oral SERD and pure ERα antagonist, that has demonstrated anti-cancer activity across a range of preclinical models, including those with ER-activating mutations.
The asset has been shown to promising anti-tumour profile when administered alone or in combination with palbociclib and thus, the company is running a Phase III trial for the same.

Dato-DXd: Daiichi Sankyo, Inc.
Datopotamab deruxtecan (Dato-DXd) is an investigational currently in Phase III for HR-positive, HER2- negative breast cancer. It is a TROP2 directed antibody drug conjugate (ADC) designed using Daiichi Sankyo's proprietary DXd ADC technology, datopotamab deruxtecan is one of the three lead ADCs in the oncology pipeline of Daiichi Sankyo, and one of the most advanced programs in AstraZeneca's ADC scientific platform.

Datopotamab deruxtecan is comprised of a humanized anti-TROP2 IgG1 monoclonal antibody, developed in collaboration with Sapporo Medical University, attached to a number of topoisomerase I inhibitor payloads, an exatecan derivative, via tetrapeptide-based cleavable linkers.

CX-2009: CytomX Therapeutics
CX-2009 is a Probody drug conjugate that consists of a humanized anti-CD166 monoclonal antibody conjugated to DM4, a potent microtubule inhibitor known to be active against multiple cancer types.
It is currently being tested in Phase II trial in Advanced HR-Positive/HER2-Negative Breast Cancer and of Praluzatamab Ravtansine as Monotherapy and in Combination with Pacmilimab (CX-072) in Advanced Triple-Negative Breast Cancer.

RGT-419B: Regor Therapeutics
RGT-419B is a new generation of CDK inhibitor with an optimized kinase activity spectrum. The clinical development program of RGT-419B is designed to address the unmet medical needs of patients who are refractory or have relapsed after previous treatment, providing new opportunities to improve survival and quality of life for patients with advanced/metastatic breast cancer.
It is currently being tested in Phase I trial in in subjects with Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Advanced/Metastatic Breast Cancer.

HR Positive/ HER2 Negative Breast Cancer Pipeline Therapeutics Assessment
There are approx. 50+ key companies which are developing therapies for HR Positive/ HER2 Negative Breast Cancer. The HR Positive/ HER2 Negative Breast Cancer companies which have their HR Positive/ HER2 Negative Breast Cancer drug candidates in the most advanced stage, i.e. phase III include, AstraZeneca.

DelveInsight's HR Positive/ HER2 Negative Breast Cancer pipeline report covers around 53+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

HR Positive/ HER2 Negative Breast Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

HR Positive/ HER2 Negative Breast Cancer Products have been categorized under various Molecule types such as
• Oligonucleotide
• Peptide
• Small molecule

Learn more about the emerging HR Positive/ HER2 Negative Breast Cancer Pipeline Therapies @ HR Positive/ HER2 Negative Breast Cancer Clinical Trials Assessment- https://www.delveinsight.com/sample-request/hr-positive-her2-negative-breast-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the HR Positive/ HER2 Negative Breast Cancer Pipeline Report
• Coverage- Global
• HR Positive/ HER2 Negative Breast Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• HR Positive/ HER2 Negative Breast Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• HR Positive/ HER2 Negative Breast Cancer Companies- Regor Therapeuics, Seagen Inc., CytomX Therapeutics, Taizhou EOC Pharma, Chia Tai Tianqing Pharmaceutical Group, AstraZeneca, Daiichi Sankyo Inc., Tyme, Inc., Seagen Inc., Context Therapeutics, Eisai Inc., Shanghai Hengrui Pharmaceutical Co. Ltd., Jiangsu Simcere Pharmaceutical Co., Kind Pharmaceuticals, Merus N.V., Atossa Therapeutics, Roche, and others.
• HR Positive/ HER2 Negative Breast Cancer Pipeline Therapies- CX-2009, CX-072, Dato-DXd, Capecitabine, Gemcitabine, OP-1250, Ribociclib, Alpelisib, Palbociclib 125mg, Cyclophosphamide, Doxorubicin, and others

Dive deep into rich insights for new drugs for HR Positive/ HER2 Negative Breast Cancer Treatment, Visit @ HR Positive/ HER2 Negative Breast Cancer Market Drivers and Barriers, and Future Perspective- https://www.delveinsight.com/sample-request/hr-positive-her2-negative-breast-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. HR Positive/ HER2 Negative Breast Cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. HR Positive/ HER2 Negative Breast Cancer- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Dato-DXd: Daiichi Sankyo, Inc.
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. CX-2009: CytomX Therapeutics
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. RGT-419B: Regor Therapeutics
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug Name: Company Name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. HR Positive/ HER2 Negative Breast Cancer- Unmet Needs
21. HR Positive/ HER2 Negative Breast Cancer- Market Drivers and Barriers
22. Appendix

For further information on the HR Positive/ HER2 Negative Breast Cancer Pipeline therapeutics, reach out to HR Positive/ HER2 Negative Breast Cancer Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/hr-positive-her2-negative-breast-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

List of Important Links-

https://faceblox.mn.co/posts/54148443
https://edpt204w19.mn.co/posts/54148617
https://monewment.mn.co/posts/54148939
https://flexi-vegan.mn.co/posts/54149020
https://network-4526.mn.co/posts/54149059
https://redline-rp.mn.co/posts/54149156
https://sparklabsglobal.mn.co/posts/54149234
https://ajodance.mn.co/posts/54149267
https://datingwithprettygirls.mn.co/posts/54149313
https://dazed.mn.co/posts/54149356
https://moons.mn.co/posts/54149384
https://network-339477.mn.co/posts/54149409
https://match-ideas.mn.co/posts/54149766
https://ceo-codes.mn.co/posts/54149864
https://thinkinvestments.mn.co/members/23360451
https://spoder.mn.co/posts/54150026
https://network-64869.mn.co/posts/54150082
https://network-4448412.mn.co/posts/54150397
https://network-90620.mn.co/posts/54150432
https://network-16648.mn.co/posts/54150462
https://a-d-n.mn.co/posts/54150499
https://fcmcommunity.mn.co/posts/54280862
https://good-stewards.mn.co/posts/54280899
https://listening-works.mn.co/posts/54280919
https://network-20540.mn.co/posts/54280968
https://healing-communities-njde.mn.co/posts/54281001
https://runite.mn.co/posts/54281382
https://jasa-seo.mn.co/posts/54281443
https://louhangaround.mn.co/posts/54281497
https://onwayassociation.mn.co/posts/54281510
https://shaman-leaders.mn.co/posts/54281625
https://virtuous-rubies.mn.co/posts/54281637
https://extinct-networks.mn.co/posts/54281691
https://kingnobleblacksupremacy.mn.co/posts/54282200
https://ledpanellights.mn.co/posts/54282336
https://diy-vision.mn.co/posts/54282407
https://digimac-technologies.mn.co/posts/54282475
https://network-89593.mn.co/posts/54282548
https://tdcommunitynetworks.mn.co/posts/54282663
https://machine-parts-toolbox.mn.co/posts/54282718
https://wecanchat.mn.co/posts/exploring-the-dynamics-of-the-uveitis-market-insights-by-delveinsight
https://jointsnmotion-hub.mn.co/posts/54283557
https://artisthub.mn.co/posts/54283657
https://global-non-profit-network.mn.co/posts/54283837
https://jointsnmotion-hub.mn.co/posts/54283943
https://network-5674633.mn.co/posts/54284190
https://where-this-business-and-businesses.mn.co/posts/54284238
https://travelwithme.social/read-blog/34900

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website:
https://www.delveinsight.com/report-store/medical-marijuana-market-insight
https://www.delveinsight.com/report-store/ranibizumab-biosimilars-insight
https://www.delveinsight.com/report-store/vital-sign-monitors-external-remote-patient-monitoring-devices-market

This release was published on openPR.